TY - JOUR
T1 - Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma
AU - Fiorentino, Alba
AU - Caivano, Rocchina
AU - Chiumento, Costanza
AU - Cozzolino, Mariella
AU - Clemente, Stefania
AU - Pedicini, Piernicola
AU - Fusco, Vincenzo
PY - 2012/12
Y1 - 2012/12
N2 - To assess the role of comorbidity on outcome in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant Temozolomide, patients over 65 years with glioblastoma, who underwent surgical resection or biopsy and radiochemotherapy, were evaluated. The Adjusted-Age Charlson Comorbidity Index and the Adult Comorbidity Evaluation-27 were used to assess comorbidity. From April 2005 to January 2011, 35 patients (median age 72 years) were treated in our Institution. Thirteen patients had a Charlson score more than 3, while, according to the Adult Comorbidity Evaluation-27, 21 patients had mild or severe comorbid conditions. Patients with low Charlson comorbidity score experienced a longer survival time than those with higher score (22 vs. 10 months, respectively). The Adjusted-Age Charlson Comorbidity Index influenced survival at univariate and multivariate analysis (p = 0.004, p = 0.001, respectively). No comorbidity index was a predictor for progression-free survival. Our data suggested that the association of radiotherapy with TMZ was safe and effective. Perhaps, the comorbidity assessment could be an appropriate tool in the treatment decision for elderly patients with glioblastoma.
AB - To assess the role of comorbidity on outcome in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant Temozolomide, patients over 65 years with glioblastoma, who underwent surgical resection or biopsy and radiochemotherapy, were evaluated. The Adjusted-Age Charlson Comorbidity Index and the Adult Comorbidity Evaluation-27 were used to assess comorbidity. From April 2005 to January 2011, 35 patients (median age 72 years) were treated in our Institution. Thirteen patients had a Charlson score more than 3, while, according to the Adult Comorbidity Evaluation-27, 21 patients had mild or severe comorbid conditions. Patients with low Charlson comorbidity score experienced a longer survival time than those with higher score (22 vs. 10 months, respectively). The Adjusted-Age Charlson Comorbidity Index influenced survival at univariate and multivariate analysis (p = 0.004, p = 0.001, respectively). No comorbidity index was a predictor for progression-free survival. Our data suggested that the association of radiotherapy with TMZ was safe and effective. Perhaps, the comorbidity assessment could be an appropriate tool in the treatment decision for elderly patients with glioblastoma.
KW - Chemotherapy
KW - Comorbidity
KW - Elderly
KW - Glioblastoma
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84880301548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880301548&partnerID=8YFLogxK
U2 - 10.1007/s12032-012-0246-4
DO - 10.1007/s12032-012-0246-4
M3 - Article
C2 - 22580816
AN - SCOPUS:84880301548
VL - 29
SP - 3467
EP - 3471
JO - Medical Oncology
JF - Medical Oncology
SN - 1357-0560
IS - 5
ER -